Therefore, [111In]In-DTPA-trastuzumab-IRDye800CW probably allows multimodal imaging of HER2-positive breast cancer in patients receiving neoadjuvant trastuzumab treatment, but further research is necessary. The gene discussed is ERBB2; the disease is breast cancer.